Pfizer Corporation

Avvari Krishna Prasad

Jin-Hwan Kim

Jianxin Gu

Rajesh Kumar Kainthan

Yu-ying Yang

Mingming Han

Mark Edward Ruppen

Annaliesa Sybil Anderson

Kathrin Ute Jansen

Srinivas Kodali

Amardeep Singh Bhupender Bhalla

Lakshmi Khandke

Cindy Xudong Yang

Philip R Dormitzer

Robert G K Donald

Ye Che

David Cooper

Ping Cai

Xin Xu

Michael William Pride

Xiayang Qiu

Kena Anne Swanson

Wendy Jo Watson

Kristin Rachael Tompkins

Lorna Del Pilar Nunez

KariAnn Sweeney Efferen

Alexey Vyacheslavovich Gribenko

Luke David Handke

Xi Song

Suddham Singh

Emilio Anthony Emini

Miguel Angel Garcia

Leena Shriram Bagle

Lei Hu

Justin Keith Moran

Paul A Liberator

Jason Arnold Lotvin

Wei Chen

Ingrid Lea Scully

Nishith Merchant

Ling Chu

Laurent Oliver Chorro

Rosalind Pan

Scott Ellis Lomberk

Karen Kiyoko Takane

Yu-Ying Yang

Kariann Sweeney Efferen

Philip Ralph Dormitzer

The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.

Glycoconjugation processes and compositions

The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

RSV F protein mutants

The invention relates to activatedserotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprisingserotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.

capsular polysaccharides and conjugates thereof

The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.

Glycoconjugation process

In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived fromlipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for differentserotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

compositions and methods thereof

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Immunogenic compositions and uses thereof

The present invention relates to new immunogenic compositions comprising conjugatedcapsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from aserotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-eT linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (I): The invention further relates to immunogenic compositions comprising such glycoconjugates, and to methods for the preparation and use of such glycoconjugates and immunogenic compositions.

Immunogenic glycoprotein conjugates

[object Object]

The present invention relates to new immunogenic compositions comprising conjugatedcapsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from aserotype not found in PREVNAR&#xae;, SYNFLORIX&#xae; and/or PREVNAR 13&#xae;. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from, commonly referred to as group B(GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Growing community of inventors

Chapel Hill, NC, United States of America

Avvari Krishna Prasad